1. Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. Issue 1 (December 2015) Authors: Bracaglia, C; Gatto, A; Pardeo, M; Lapeyre, G; Ferlin, W; Nelson, R; de Min, C; De Benedetti, F Journal: Pediatric rheumatology online journal Issue: Volume 13:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. Issue 1 (December 2015) Authors: Bracaglia, C; Gatto, A; Pardeo, M; Lapeyre, G; Ferlin, W; Nelson, R; de Min, C; De Benedetti, F Journal: Pediatric rheumatology online journal Issue: Volume 13:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS. Issue 1 (December 2015) Authors: Bracaglia, C; Marafon, D; Caiello, I; de Graaf, K; Guilhot, F; Ferlin, W; Davì, S; Schulert, G; Ravelli, A; Grom, A; Nelson, R; de Min, C; De Benedetti, F Journal: Pediatric rheumatology online journal Issue: Volume 13:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS. Issue 1 (December 2015) Authors: Bracaglia, C; Marafon, D; Caiello, I; de Graaf, K; Guilhot, F; Ferlin, W; Davì, S; Schulert, G; Ravelli, A; Grom, A; Nelson, R; de Min, C; De Benedetti, F Journal: Pediatric rheumatology online journal Issue: Volume 13:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Interferon gamma (IFNg) drives disease in the TLR9-mediated cytokine storm syndrome in mice. Issue 1 (December 2015) Authors: de Min, C; Buatois, V; Chatel, L; Cons, L; De Benedetti, F; Kosco-Vilbois, M; Ferlin, W Journal: Pediatric rheumatology online journal Issue: Volume 13:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation. Issue 1 (December 2015) Authors: Prencipe, G; Caiello, I; Bracaglia, C; de Min, C; De Benedetti, F Journal: Pediatric rheumatology online journal Issue: Volume 13:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation. Issue 1 (December 2015) Authors: Prencipe, G; Caiello, I; Bracaglia, C; de Min, C; De Benedetti, F Journal: Pediatric rheumatology online journal Issue: Volume 13:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗